Revenio Group Oyj

Board/Management Information • Oct 4, 2022

Changes in the Revenio Group Corporation's Leadership team

Revenio Group Corporation, Stock Exchange Release, October 4, 2022 at 3.30 pm (EEST)

Changes in the Revenio Group Corporation's Leadership Team

Mika Salkola, Revenio Group Corporation's Vice President of Research, has retired as of 4 October 2022. Salkola has worked as a Director of Product Development and Research at iCare Finland Oy, a subsidiary of Revenio Group Corporation, since 2015, and has been a member of the Revenio Group's Leadership team since 2018.

"I would like to thank Mika for his excellent work in his key role on iCare's product development, and for sharing his unique expertise to our product development team. Through his visionary work, the company has evolved into an innovative pioneer of eye disease screening and monitoring", says Jouni Toijala, CEO of Revenio.

M.Sc. Eng. Giuliano Barbaro, Vice President, Devices, will take over the responsibility for research management in addition to product development as of 4 October 2022. He has been a member of Revenio's Leadership team since 2020.

"This was a logical transition for Giuliano Barbaro to take on a broader product development portfolio. I am confident that Giuliano, with his strong product development and industry expertise, is the right person to lead Revenio's product development into a new era. His extensive experience in CenterVue S.p.A.'s demanding product development also supports Revenio's strong internationalization strategy", says CEO Jouni Toijala.

Revenio Group Oyj

Further information

CEO Jouni Toijala, tel. +358 50 484 0085 jouni.toijala@revenio.fi

Distribution Nasdaq Helsinki Oy Key media www.revenio.fi

Revenio Group in brief

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical

software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2021, the Group's net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

Changes in the Revenio Group Corporation's Leadership team